Welcome, Introductions, and Goals for Workshop
Paul Meltzer, M.D., Ph.D., Center for Cancer Research, National Cancer Institute
Steve Groft, Pharm.D., Office of Rare Diseases, National Institutes of Health

Session I: Update on the 2007 Chordoma Research Roadmap
Moderator: Paul Meltzer, M.D., Ph.D.

Summary of First International Chordoma Research Workshop in May 2007
Francis Collins, M.D., Ph.D., National Human Genome Research Institute

Laying the Foundation—the Chordoma Foundation’s First Year and Beyond
Josh Sommer, Chordoma Foundation
Simone Sommer, M.D., M.P.H., Chordoma Foundation

Clinical Overview of Chordoma
Fran Hornicek, M.D., Ph.D., Massachusetts General Hospital


Session II: New Research on the Genetics and Genomics of Chordoma Moderator: Francis Collins, M.D., Ph.D.

High-Resolution Profiling of the Chordoma Genome
Paul Meltzer, M.D., Ph.D.

Application of Expression Analysis to Chordoma
Mike Kelley, M.D., Duke University

TSC/mTOR Pathway in Chordomas
Vijaya Ramesh, Ph.D., Massachusetts General Hospital

Systems Approaches to Dissecting Signaling Pathways in Chordoma
Ramnik Xavier, M.D., Massachusetts General Hospital


Session III: Chordoma Development and Pathogenesis
Moderator: Justin Cates, M.D., Ph.D., Vanderbilt University Medical Center

Development of the Notochord
Derek Stemple, Ph.D., Wellcome Trust Sanger Institute

Developing a Mouse Model for Chordoma
Brian Harfe, Ph.D., University of Florida

The Tale of the Ferret: What We Know of Ferret Notochord and Chordoma
Andrew Rosenberg, M.D., Massachusetts General Hospital

Clinical Results in a Series of 71 Clival Chordomas and Correlation of Survival to the Expression of E and N Cadherins
Chandranath Sen, M.D., St. Luke’s Roosevelt Hospital

Potential Therapeutic Targets for Chordoma
Nadege Presneau, Ph.D., University College London Cancer Institute


Session IV: Targeted Treatment Development
Moderator: Chris Austin, M.D., National Human Genome Research Institute

Update of a Phase II Study of Sunitinib for Recurrent/Metastatic Chordoma and Other Sarcomas
Robert Maki, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center

In Vitro Characterization of Chordoma Cells
Deric Park, M.D., University of Pittsburgh Cancer Institute

Rationale for Tyrosine Kinase Inhibitors in Chordomas
Elena Tamborini, Ph.D., Fondazione IRCCS Istituto Nazionale dei Tumori

Developing Rationally Targeted Therapies for Chordoma: What Can Be Learned from Other Forms of Sarcoma?
George Demetri, M.D., Dana-Farber/Harvard Cancer Center

Brachyury-Targeted T-Cell Immune Therapy for Chordoma
Claudia Palena, Ph.D., National Cancer Institute

High-Throughput Small Molecule Screening in Chordoma
Chris Austin, NIH Chemical Genoics Center


Poster Session Discussion
Moderator: Chandranath Sen

A Long-Term Follow-up Study of Skull Base Chordomas Factors Influencing the Survival of Patients with Skull Base Chordoma
Jie Tang, M.D., Beijing Tiantan Hospital

Prognostic Value of Cytogenetic Abnormalities in Skull Base Chordoma
Svetlana Pravdenkova, M.D., University of Arkansas for Medical Sciences

Proton-Beam Irradiation in Treatment of Sacral Chordomas
Lilia Loredo, M.D., Loma Linda University Medical Center

Carbon Ion Radiotherapy for Sacral Chordomas
Tadashi Kamada

Carbon Ion Treatment Workflow and Future Radiation Therapy Concepts in the Treatment of Chordomas in Germany
Anna Nikoghosyan, M.D, University of Heidelberg

Anatomic Study About the Construction, Distribution, and Anastomosis of Arteries that Supply Sacrum
Huilin Yang, First Affiliated Hospital of Soochow University 

Investigation of the Biomechanical Implications of Sacrectomy and Study of Biomechanical Rationale for Sacral Prosthesis After Total Sacrectomy
Huilin Yang, First Affiliated Hospital of Soochow University

Ecchordosis Physaliphora Sphenooccipitalis Versus Benign Notochordal Cell Tumor
Takehiko Yamaguchi, M.D., Ph.D., Sapporo Medical University School of Medicine

Dinner and Guest Speaker: From Bench to Bedside—the Development ErbB2
Neil Spector, M.D., Duke University Cancer Center

Session V: Local Control of Chordoma
Moderator: Fran Hornicek, M.D., Ph.D.

Surgical Advances for Chordomas in Base of Skull Surgery
Amin Kassam, M.D., University of Pittsburgh Medical Center

Surgical Advances for Chordoma of the Spine
Jean-Paul Wolinsky, M.D., Johns Hopkins University

 Radiation Therapy in the Management of Chordomas
Tom DeLaney, M.D., Massachusetts General Hospital


Session VI: New Approaches to Chordoma Therapy  
Moderator: Deric Park

Liposomes: A Platform for Imaging and Treating Chordoma
Srinivasan Mukundan, Ph.D., M.D., Duke University Medical Center

Can the HMW-MAA Help Us Counteract the Immunoescape Mechanisms Used by Tumor Cells?
Soldano Ferrone, M.D., Ph.D., University of Pittsburgh Medical Center

Signaling Pathways in Chordoma for Therapeutic Intervention
Neil Spector, M.D., Duke University Cancer Center

Treatment Development for Chordoma Using Sarcoma Research Paradigms
Laurence Baker, D.O., University of Michigan


Session VII: Developing Chordoma Practice Guidelines 
Moderator: Dean Chou, M.D., University of California, San Francisco

Pathology Consensus Report
Andrew Rosenberg, M.D

Developing Chordoma Practice Consensus Guidelines
Fran Hornicek, M.D., Ph.D

Specific Considerations for Pediatric Chordoma Patients
Amin Kassam, M.D, Chandranath Sen, M.D, and  Norbert Liebsch, M.D., Ph.D., Massachusetts General Hospital

Breakout  Working Groups

• Clinical Management
• Mechanisms of Disease
• Therapeutic Development

Breakout Group Reports
Moderator: Paul Meltzer

Clinical Management
Franco DeMonte & Tom DeLaney

Mechanisms of Disease
Derek Stemple & Dilys Parry

Therapeutic Development
Mike Kelley & Larry Baker


Strategies for Resource Development
Isis Mikhail, M.D., M.P.H., Dr.P.H., National Cancer Institute

Action Planning-Agree on Research Priorities and Define Next Steps
Moderators: Mike Kelley, Amin Kassam, Fran Hornicek, and Simone Sommer